Headache and Migraine

The director of the MedStar Georgetown Headache Center discussed the barriers to patient and clinician education in migraine and the gap in available interventions for the diverse patient population.

The investigators noted that these data provide robust and promising evidence that eptinezumab is associated with a rapid preventive effect in chronic migraine that is sustained for 3 months after a single infusion.

Your patient asks if a ketogenic diet can reduce her migraines. What will you tell her?

The chief medical officer of electroCore discussed the various data which have been published on the use of noninvasive vagus nerve stimulation in different populations of patients with migraine and headache.

The director of headache medicine and chief of general neurology at Yale Medicine discussed the long-term success the new preventive migraine therapies have shown thus far, and how the lack of safety concerns will improve how they’re utilized.

Epidemiology studies are useful to clinicians because they highlight diagnosis and prescribing patterns, common trends within a disease, and unmet needs.

The clinical professor of neurology at Albert Einstein College of Medicine discussed the referral process for patients with migraine and which patients may be too complex for the limited time primary care physicians have.

This week’s edition features highlights from NeurologyLive’s coverage of the American Headache Society’s annual scientific meeting.

The professor of neurology, neurotherapeutics, and ophthalmology at UT Southwestern discussed the need to better coordinate care between providers when telemedicine is being utilized in headache and migraine care.

The monoclonal antibody against CGRP reduced the frequency of episodic cluster headache attacks significantly more than placebo, though the Eli Lilly therapy failed to separate from placebo in the disease’s chronic presentation.

For years, study participants had been suffering with migraine symptoms and had failed at least three to five therapies before enrolling in the trial.

The director of the Headache Center of Southern California shared insight into the success of ubrogepant in patients who failed on triptans, and how the future of migraine treatment may need to focus on combination approaches.

The director of the MedStar Georgetown Headache Center spoke about the higher-than-desired rates of opioid prescriptions for patients with migraine, and how new treatment options and provider education can help lower those numbers.

At the recent American Headache Society meeting, researchers detailed the manifold risks of opioid use in patients with migraine.

The director of the Orange County Migraine and Headache Center spoke about the adherence issues in acute migraine treatment and how the safety profile of investigational medications such as rimegepant and ubrogepant suggests they may be able to address them.

Lead author Elizabeth K. Seng, PhD, shared insight into the findings of an exploration of the use of mindfulness-based cognitive therapy to reduce the impact of migraine on patients, as measured by Migraine Disability Assessment, as well as Headache Disability Inventory scores.

The International Congress on the Future of Neurology will take place this Fall in New York City, converging experts in neurology to discuss the latest data and best practices to better inform clinical decision-making.

Investigators found that participants struggled to adhere to the treatment protocol, which required them to administer 3 treatments per day.

The director of headache medicine and chief of general neurology at Yale Medicine spoke about the significance of having CGRP inhibitors in migraine treatment, and how eptinezumab fits into the treatment landscape.

No differences were observed in the magnitude of ubrogepant treatment effect between defined triptan subgroups.

The clinical professor of neurology at Albert Einstein College of Medicine spoke about the trends revealed by the OVERCOME study, and how this data can be used to improve the management of the millions of patients with migraine in the US.

The director of the Montefiore Headache Center and professor of neurology at Albert Einstein College of Medicine spoke about the results of an analysis of eptinezumab’s effect on the severity of migraine and its impact on patients’ lives.

Atogepant significantly reduced mean monthly migraine days compared to placebo across a number of doses and was generally well-tolerated, with no treatment-related serious adverse events.

Real-world data of erenumab indicates that a large number of patients are the chronic migraine population, and there is a high rate of persistence to the anti-CGRP therapy. The most commonly prescribed dose of erenumab was 70 mg.

Patients with migraine who reported both moderate and severe pain intensity during headache attacks experienced high rates of relief and freedom from pain and their most bothersome symptom when treated with 3-mg sumatriptan injection, DFN-11.

An analysis of the open-label PREVAIL trial demonstrated a magnitude of therapeutic effect for eptinezumab that was either maintained or improved with subsequent infusions.

The professor of neurology, neurotherapeutics, and ophthalmology at UT Southwestern spoke about the potential of telemedicine in headache medicine, as well as the findings from a single-center, 45-patient study.

Despite ongoing discussion regarding the 6-item Headache Impact Test’s relevance in the migraine population—for which it was not specifically developed—the test has been shown to be a useful tool in the assessment of patients with migraine.

The director of the MedStar Georgetown Headache Center spoke about ubrogepant’s long-term safety and efficacy and its potential to fill the large gap that remains in acute migraine care.

Patients with migraine rated their telemedicine visits as more convenient with shorter visit times; two factors that can also benefit providers.